Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon for EPI in Type 2 Diabetes
NCT02009410Phase 4Withdrawn
- Sponsor
- Abbott Laboratories
- Start
- Nov 2013
- Primary completion
- Aug 2014
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
A Phase 4 trial of LipaCreon in exocrine pancreatic insufficiency (EPI), sponsored by Abbott Laboratories. Planned start Nov 2013; status: withdrawn.
02
Drugs
LipaCreon
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT02009410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009410.